Investigational Drug Information for Onapristone
✉ Email this page to a colleague
What is the drug development status for Onapristone?
Onapristone is an investigational drug.
There have been 11 clinical trials for Onapristone.
The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2023.
The most common disease conditions in clinical trials are Breast Neoplasms, Endometrial Neoplasms, and Prostatic Neoplasms. The leading clinical trial sponsors are Context Therapeutics, Context Therapeutics Inc., and Arno Therapeutics.
There are zero US patents protecting this investigational drug and zero international patents.
Summary for Onapristone
| US Patents | 2,141 |
| International Patents | 10,166 |
| US Patent Applications | 5,591 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 1,563 |
| Clinical Trial Progress | Phase 2 (2023-06-01) |
| Vendors | 21 |
Recent Clinical Trials for Onapristone
| Title | Sponsor | Phase |
|---|---|---|
| A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer | Context Therapeutics Inc. | PHASE1 |
| Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer | Context Therapeutics Inc. | Phase 1/Phase 2 |
| Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study) | Context Therapeutics | Phase 2 |
Clinical Trial Summary for Onapristone
Top disease conditions for Onapristone
Top clinical trial sponsors for Onapristone
US Patents for Onapristone
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Onapristone | ⤷ Start Trial | Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus | Seattle Genetics, Inc. (Bothell, WA) | ⤷ Start Trial |
| Onapristone | ⤷ Start Trial | Anti-FGFR3 antibodies and methods using same | Genentech Inc | ⤷ Start Trial |
| Onapristone | ⤷ Start Trial | Bispecific antigen-binding constructs targeting HER2 | Zymeworks BC Inc | ⤷ Start Trial |
| Onapristone | ⤷ Start Trial | Method of diagnosing and treating cancer using B-catenin splice variants | The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC) | ⤷ Start Trial |
| Onapristone | ⤷ Start Trial | Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers | Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC) | ⤷ Start Trial |
| Onapristone | ⤷ Start Trial | Methods for sensitizing a quiescent cancer stem cell to a BCR-ABL inhibitor | The Regents of the University of California (Oakland, CA) | ⤷ Start Trial |
| Onapristone | ⤷ Start Trial | Use of inhibitors of Bruton'S tyrosine kinase (Btk) | Pharmacyclics LLC (Sunnyvale, CA) | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Onapristone
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Onapristone | Australia | AU2006269422 | 2025-07-07 | ⤷ Start Trial |
| Onapristone | Canada | CA2614436 | 2025-07-07 | ⤷ Start Trial |
| Onapristone | European Patent Office | EP1917020 | 2025-07-07 | ⤷ Start Trial |
| Onapristone | European Patent Office | EP2722051 | 2025-07-07 | ⤷ Start Trial |
| Onapristone | European Patent Office | EP3498289 | 2025-07-07 | ⤷ Start Trial |
| Onapristone | Spain | ES2585357 | 2025-07-07 | ⤷ Start Trial |
| Onapristone | Spain | ES2708763 | 2025-07-07 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
